Hello, Fool! | Login | Signup | My Fool
Aug 21, 2008 9:32 PM ET | Site Changes | Help
A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.
View All Commentary (AMLN)
Recs
Carol1776 (< 20) Submitted: 2/18/07 5:30 PM : Start Price: $39.93 AMLN Score: -20.98
Byetta P3 trial with improved dosing regimen completes this year. Patients
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK